Trade Ocugen, Inc. - OCGN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0108 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.8899 |
| Open | 0.888 |
| 1-Year Change | 131.61% |
| Day's Range | 0.8874 - 0.919 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 22, 2024 | 0.8970 | -0.0008 | -0.09% | 0.8978 | 0.9191 | 0.8819 |
| Nov 21, 2024 | 0.8899 | -0.0070 | -0.78% | 0.8969 | 0.9310 | 0.8869 |
| Nov 20, 2024 | 0.9120 | 0.0156 | 1.74% | 0.8964 | 0.9310 | 0.8479 |
| Nov 19, 2024 | 0.8748 | -0.0361 | -3.96% | 0.9109 | 0.9119 | 0.8597 |
| Nov 18, 2024 | 0.9147 | -0.0222 | -2.37% | 0.9369 | 0.9569 | 0.8978 |
| Nov 15, 2024 | 0.9357 | -0.0612 | -6.14% | 0.9969 | 0.9969 | 0.9329 |
| Nov 14, 2024 | 0.9969 | 0.0300 | 3.10% | 0.9669 | 1.0669 | 0.9469 |
| Nov 13, 2024 | 0.9551 | -0.0518 | -5.14% | 1.0069 | 1.0369 | 0.9472 |
| Nov 12, 2024 | 1.0169 | -0.0100 | -0.97% | 1.0269 | 1.0469 | 0.9969 |
| Nov 11, 2024 | 1.0469 | 0.0400 | 3.97% | 1.0069 | 1.0669 | 1.0069 |
| Nov 8, 2024 | 0.9827 | -0.0842 | -7.89% | 1.0669 | 1.1169 | 0.9468 |
| Nov 7, 2024 | 1.0569 | 0.0000 | 0.00% | 1.0569 | 1.0869 | 1.0369 |
| Nov 6, 2024 | 0.9850 | 0.0270 | 2.82% | 0.9580 | 0.9948 | 0.9443 |
| Nov 5, 2024 | 0.9438 | -0.0031 | -0.33% | 0.9469 | 0.9553 | 0.9269 |
| Nov 4, 2024 | 0.9474 | 0.0205 | 2.21% | 0.9269 | 0.9678 | 0.9069 |
| Nov 1, 2024 | 0.9378 | 0.0209 | 2.28% | 0.9169 | 0.9514 | 0.9119 |
| Oct 31, 2024 | 0.9115 | -0.0604 | -6.21% | 0.9719 | 0.9719 | 0.9001 |
| Oct 30, 2024 | 0.9699 | 0.0134 | 1.40% | 0.9565 | 1.0069 | 0.9275 |
| Oct 29, 2024 | 0.9522 | -0.0647 | -6.36% | 1.0169 | 1.0269 | 0.9479 |
| Oct 28, 2024 | 0.9969 | 0.0540 | 5.73% | 0.9429 | 1.0269 | 0.9269 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Ocugen, Inc. Company profile
Ocugen (OCGN) is a biopharmaceutical company focusing on discovering, developing, and commercialising gene therapies to cure blindness illnesses and creating a Covid-19 vaccine.
Founded in 2006, Ocugen became a public company in 2014. The company’s shares are traded on the Nasdaq under the symbol OCGN.
Projects in the pipeline are Covid-19 vaccines, a Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases.
For the Covid-19 vaccine, the company, in collaboration Bharat Biotech, was developing, manufacturing and commercialising COVAXIN for the prevention of the disease for US and Canada markets. COVAXIN is a whole-virion inactivated Covid-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus.
The Modifier Gene Therapy Platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The technology is licensed from the Schepens Eye Research Institute of Massachusetts Eye and Ear (Harvard Medical School).
The company is developing OCU200, a biologic product candidate for the treatment of severe vision-threatening diseases such as diabetic macular edema (DME), diabetic retinopathy (DR), and wet age-related macular degeneration (Wet-AMD).
Patients affected by these diseases have common symptoms, such as blurry vision and increasing visual loss as the condition develops.
Another technology in the pipeline is OCU400, the company’s first product candidate developed with its Modifier Gene Therapy Platform.
Ocugen is headquartered in Malvern, Pennsylvania.
| Industry: | Biotechnology & Medical Research (NEC) |
11 Great Valley Parkway
MALVERN
PENNSYLVANIA 19355
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com